标题
Discontinued drug therapies to treat diabetes in 2015
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 26, Issue 2, Pages 219-225
出版商
Informa UK Limited
发表日期
2016-12-21
DOI
10.1080/13543784.2017.1274732
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Lessons From Peglispro: IMAGINE How to Improve Drug Development and Affordability
- (2016) Matthew C. Riddle DIABETES CARE
- Diabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’
- (2016) M. A. Skow et al. DIABETES OBESITY & METABOLISM
- Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial
- (2016) M. J. Davies et al. DIABETES OBESITY & METABOLISM
- Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes
- (2015) N. B. Amin et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
- (2015) T. Karagiannis et al. DIABETES OBESITY & METABOLISM
- Discontinued drug therapies to treat diabetes in 2014
- (2015) Jerry R Colca EXPERT OPINION ON INVESTIGATIONAL DRUGS
- GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
- (2015) Donna Ryan et al. Obesity
- NorLeu3-Angiotensin (1-7) [DSC127] as a Therapy for the Healing of Diabetic Foot Ulcers
- (2015) Kathleen E. Rodgers et al. Advances in Wound Care
- Discontinued in 2013: diabetic drugs
- (2014) Maka S Hedrington et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Recent Advances in the Development of Acetyl-CoA Carboxylase (ACC) Inhibitors for the Treatment of Metabolic Disease
- (2014) Matthew P. Bourbeau et al. JOURNAL OF MEDICINAL CHEMISTRY
- Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus
- (2013) V. P. Sinha et al. DIABETES OBESITY & METABOLISM
- AZD5213: a novel histamine H3 receptor antagonist permitting high daytime and low nocturnal H3 receptor occupancy, a PET study in human subjects
- (2012) Aurelija Jucaite et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- The Glucagon Receptor Is Involved in Mediating the Body Weight-Lowering Effects of Oxyntomodulin
- (2012) Jennifer R. Kosinski et al. Obesity
- Targeting Acetyl-CoA Carboxylases: Small Molecular Inhibitors and their Therapeutic Potential
- (2012) Di-Xian Luo et al. Recent Patents on Anti-Cancer Drug Discovery
- Academic perspectives on the United States food and drug administration's guidance for industry on diabetes mellitus
- (2010) Charles H. Hennekens et al. Contemporary Clinical Trials
- The 11- -Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy
- (2010) J. Rosenstock et al. DIABETES CARE
- Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
- (2009) A. Pocai et al. DIABETES
- A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
- (2009) Jonathan W Day et al. Nature Chemical Biology
- Time of the day for 11β-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice
- (2008) M. M. Véniant et al. DIABETES OBESITY & METABOLISM
- Diabetic neuropathy: Mechanisms to management
- (2008) James L. Edwards et al. PHARMACOLOGY & THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started